Ciprofloxacin utility as antifibrotic in the skin of patients with scleroderma

Journal of Dermatology

Volumn 37, Issue 4, 2010, Pages 323-329

  Rubén, Enríquez Casillas ^a,c   Manuel, Vázquez Rodríguez ^a   Agustín, Ochoa Ramírez ^a   Huerta, Miguel ^b   Antonio, Fraga Mouret ^a   Iván, Delgado Enciso ^c  

^a Mexican Institute for Social Security   (Mexico)

^b University Center for Biomedical Research   (Mexico)

^c UNIVERSIDAD DE COLIMA   (Mexico)

Author keywords

Antifibrotic; Ciprofloxacin; Scleroderma

Indexed keywords

CIPROFLOXACIN; PLACEBO; PREDNISONE;

ADULT; ARTICLE; BLOOD EXAMINATION; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE SEQUENCE; DRUG MECHANISM; DRUG TOLERANCE; DRUG UTILIZATION; FEMALE; HUMAN; KIDNEY FUNCTION; LEUKOCYTURIA; LIVER FUNCTION; MALE; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; SCLERODERMA; SKIN EXAMINATION; SKIN INDURATION; SKINFOLD THICKNESS; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; CIPROFLOXACIN; FEMALE; FIBROSIS; HUMANS; KIDNEY; LIVER; MALE; MIDDLE AGED; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SKIN;

EID: 77950254149     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2010.00826.x     Document Type: Article

References (36)

1. Black CM. Tic skin-thin hypothesis: the aetiopathogenesis of systemic sclerosis. J R Coll Physicians Lond 1995 29 : 119 130.
2. Kahari VM. Activation of dermal connective tissue in scleroderma. Ann Med 1993 25 : 511 518.
3. Medsger TA, Clemens PJ, Furst DE. Systemic Sclerosis. Lippincott Williams & Wilkins, Philadelphia 2004.
4. Lin AT, Clements PJ, Furst DE. Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis. Rheum Dis Clin North Am 2003 29 : 409 426.
5. Hoyles RK, Ellis RW, Wellsbury J et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006 54 : 3962 3970.
6. Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006 354 : 2655 2666.
7. Tashkin DP, Elashoff R, Clements PJ et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007 176 : 1026 1034.
8. Khanna D, Furst DE, Clements PJ, Tashkin DP, Eckman MH. Oral cyclophosphamide for active scleroderma lung disease: a decision analysis. Med Decis Making 2008 28 : 926 937.
9. Burkhardt JE. Histologic and histochemical changes in articular cartilages of immature beagles dogs dosed whit dofloxacin, a fluoroquinolone. Vet Pathol 1990 3 : 162 170.
10. Burkhardt JE. Effects of difloxacin on the metabolism of glycosaminoglycans and collagen in organ cultures of articular cartilages. Fundam Appl Toxicol 1993 2 : 257 263.
11. Yoon JH. The effect of enrofloxacin on cell proliferation and proteoglycan in horse tendon cells. Cell Biol Toxicol 2004 1 : 41 44.
12. Sendzik J, Shakibaei M, Schäfer-Korting M, Stahlmann R. Fluoroquinolones cause changes in extracellular matrix signaling proteins, metalloproteases and caspase-3 in cultured human tendon cells. Toxicology 2005 212 : 24 36.
13. Over KE, Bucknall RC. Regression of skin changes in a patient with systemic sclerosis following treatment for bacterial overgrowth with ciprofloxacin. Br J Rheumatol 1998 37 : 696.
14. Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979 22 : 130 140.
15. Brennan P, Silman AJ, Black CM et al. Reliability of skin involvement measures in scleroderma. Scleroderma study group. Br J Rheumatol 1992 31 : 457 460.
16. Seibold JR. Scleroderma. In : Kelley WWN, Harris ED, eds. Textbook of Rheumatology. Philadelphia : WB Saunders, 1997 1133 1162.
17. Akesson A. Cyclophosphamide therapy for Scleroderma. Curr Opin Rheumatol 1998 10 : 579 583.
18. Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol 2002 38 : 99 105.
19. Seibold JR, Furst DE. Why everything (or nothing) seems to work in the treatment of Scleroderma? J Rheumatol 1992 19 : 673 676.
20. Clemens PJ, Furst DE, Seibold JE. Controlled trials: trial design issues. In : Clemens PJ, Furst DE eds. Systemic Sclerosis. Baltimore : Williams & Wilkins, 1995 515 533.
21. White B, Bauer EA, Goldsmith LA. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease modifying interventions. The American College of Rheumatology. Committee on design and outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum 1996 38 : 351 360.
22. Seibold JR, McCloskey DA. Skin involvement as a relevant outcome measure in clinical trials of systemic sclerosis. Curr Opin Rheumatol 1997 9 : 571 575.
23. Merker AP. Current estatus of outcome measure development for clinical trial in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2004 30 : 1630 1647.
24. Clemens PJ, Furst DE, Wen K. High dose versus low dose d-penicillamine in early diffuse systemic sclerosis. Analysis of a two-year, double-blind, randomized, controlled clinical trial. Artritis Rheum 1999 42 : 1194 1203.
25. Black CM, Silman AJ. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999 42 : 299 305.
26. Moser M, Zhang I. Effect on peoperative interventions, on outcome following liver resection in a rat model of cirrhosis. J Hepatol 2000 32 : 287 292.
27. Zhang M, Sonz G. Effects of hepatic stimulation substance and ciprofloxacin on cirrhosis in the rat. Gastroenterology 1996 110 : 1150 1155.
28. Asano Y, Ihn H. Clinical signiificance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis. Rheumatology 2006 45 : 303 307.
29. Dulhoff A. Immunomodulatory effects of quinolones. Lancet Infect Dis 2003 6 : 359 371.
30. Ogrendik M. Treatment of ankylosing spondylitis with moxifloxacin. South Med J 2007 100 : 366 370.
31. Weiss T, Shalit I, Blau H et al. Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of syntesis of proinflammatory cytokines. Antimicrob Agents Chemother 2004 48 : 1974 1982.
32. Williams PJ III., Attia E. The effect of ciprofloxacin on tendon, paratenon and capsular fibroblast metabolism. Am J Sports Med 2000 3 : 364 369.
33. Lazzeri M, Beneforti F. Vesical dysfunction in systemic sclerosis. J Urol 1995 153 : 1184 1187.
34. Minervini R, Morelli G. Bladder involvement in systemic sclerosis. Eur Urol 1998 34 : 47 52.
35. Czaja CA, Hooton TM. Update on acute uncomplicated urinary tract infection in women. Postgrad Med 2006 119 : 39 45.
36. Clements PJ, Lachenbruch PA, Seibold JR et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993 20 : 1892 1896.